Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons regarding their holdings in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes resulting from a dividend reinvestment plan.
Material Changes
The filing details an increase in share interests for specific individuals following the reinvestment of the dividend paid on April 12, 2012. The transaction price was 1,408.31 pence per ordinary share. Specific increases include:
- Sir Andrew Witty: 1,023 shares
- Lady Caroline Witty: 2,509 shares
- Dr D Pulman: 526 shares
- Mrs C R Pulman: 107 shares
- Mr I W Whyte: 131 shares
- Mrs V A Whyte: No change reported
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Confirm the dividend reinvestment price of 1,408.31 pence per share.
- Verify the specific share count increases for named directors and connected persons.
- Note that this filing contains no operational or financial performance data for the period.